Vernalis PLC Regulatory News (VER)

21 Dec 2005 14:30

Vernalis PLC21 December 2005 Senior Management interest in options over 5p Ordinary Shares Vernalis plc (LSE: VER, NASDAQ: VNLS) announces that the following options overnew ordinary shares of 5p each in the Company were granted to senior managementon 21 December 2005. Name No. of shares under option Exercise priceS McBrinn 350,000 62.75 pence The options are exercisable between three and ten years following grant providedthe performance target, which measures share price growth against the FTSE SmallCap Index, has been satisfied. No options will vest if performance is belowmedian; 50 per cent of the shares under option will vest at median and therewill only be full vesting if the Company's share price performance is in theupper quartile (with options vesting pro rata between median and upperquartile). - ends - Enquiries:Vernalis plc +44 (0) 118 977 3133Simon Sturge, Chief ExecutiveTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0) 20 7404 5959Jon ColesWendel Verbeek About Vernalis Vernalis is a specialty pharmaceutical company primarily focused on drugs forthe treatment of neurology and central nervous system disorders. The company hastwo marketed products, frovatriptan and Apokyn(R), and five products in clinicaldevelopment. Vernalis has collaborations with leading, global pharmaceuticalcompanies including Novartis, Biogen Idec and Serono and is establishing a NorthAmerican commercial operation to promote Apokyn(R) and co-promote frovatriptanalongside its North American licensing partner, Endo Pharmaceuticals, propellingthe company towards its goal of becoming a sustainable, self-funding, R&D-driven, specialty pharmaceutical company primarily focused on drugs for thetreatment of neurology and central nervous system disorders. For furtherinformation about Vernalis, please visit www.vernalis.com Safe Harbour statement: this news release may contain forward-looking statementsthat reflect the Company's current expectations regarding future events.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the successfulintegration of completed mergers and acquisitions and achievement of expectedsynergies from such transactions, and the ability of the Company to identify andconsummate suitable strategic and business combination transactions. This information is provided by RNS The company news service from the London Stock Exchange